Home ▶ Unknown
Outside Organization Sessions

Sunday, May 15, 2016
12:15 - 1:15 p.m.
L1 Generic Drug Development for Respiratory Products: U.S. Food and Drug Administration Update
L2 Insights into Asthma Severity from the Inner-City Asthma Consortium
L3 Indoor Exposure to Biomass/Woodsmoke Exposure and Pulmonary Health
L4 Updates on Patient-Centered Outcome Research Institute (PCORI): PCORnet and Evidence to Action Networks
L5 Prematurity and Respiratory Outcomes Program (PROP): Respiratory Outcomes at One Year
L6 Molecular Atlas of Lung Development
L7 New Insights About Severe Asthma from the NHLBI Severe Asthma Research Program
L8 Lessons Learned from the NHLBI-Sponsored Tuberculosis System Biology Program
L9 Behavior to Biomarkers: Research from the Tobacco Regulatory Science Program
Monday, May 16, 2016
12:15 - 1:15 p.m.
L11 FDA Regulation of Tobacco Products in the U.S.: 2016 Update
L12 NASA's Satellites and Models to Study the Environment And Diseases
L13 Sleep Research in the VA: Genes, Comorbidities, and Gender
L14 Update from CDC's National Asthma Control Program
L15 Endotypes and Phenotypes: A Basis For Precision-Based Medicine in COPD, the Subpopulations and Intermediate Outcome Measures in COPD Study (Spiromics)
L16 Viruses and Bacteria in Asthma Across the Ages
L17 Education Research in Sleep Health and Sleep-Circadian Biology
L18 How The NHLBI K12 Program Is Advancing our Knowledge in the Omics of Lung Disease
L19 Genetic Basis of Idiopathic Pulmonary Fibrosis
Wednesday, May 18, 2016
12:15 - 1:15 p.m.
L21 Late Breaking Results for the ALA-ACRC LASST Study
L22 Respiratory Hazards of Working with Metals: From Macrophages to Microbiomes
L23 Pulmonary Update from the U.S. Food and Drug Administration
L24 Research Funding Opportunities
L25 New Results from the COPDGene Study
L26 Enhanced Phenotyping of Pulmonary Vascular Diseases
L27 Oxidant Stress in HIV-Related Chronic Lung Disease
L28 NHLBI PETAL Clinical Trial Network: Prevention and Early Treatment of Acute Lung Injury